Compare LAES & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | CLLS |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | Switzerland | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 394.4M |
| IPO Year | 2022 | 2014 |
| Metric | LAES | CLLS |
|---|---|---|
| Price | $1.47 | $1.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $5.88 | $4.83 |
| AVG Volume (30 Days) | ★ 3.6M | 98.3K |
| Earning Date | 09-11-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.43 | N/A |
| Revenue Next Year | $41.92 | $10.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.88 |
| 52 Week High | $7.26 | $5.45 |
| Indicator | LAES | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 24.30 | 38.78 |
| Support Level | N/A | $0.88 |
| Resistance Level | $2.56 | $2.99 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 7.76 | 57.67 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.